Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Register for Updates

Sign up for our Healthcare Professional Updates

Please provide more information so we can provide you the most relevant information.

By clicking this button, you agree to our Terms. We are committed to your Privacy.